These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1193 related articles for article (PubMed ID: 25896705)
1. Antifungal susceptibility profiles of bloodstream yeast isolates by Sensititre YeastOne over nine years at a large Italian teaching hospital. Posteraro B; Spanu T; Fiori B; De Maio F; De Carolis E; Giaquinto A; Prete V; De Angelis G; Torelli R; D'Inzeo T; Vella A; De Luca A; Tumbarello M; Ricciardi W; Sanguinetti M Antimicrob Agents Chemother; 2015 Jul; 59(7):3944-55. PubMed ID: 25896705 [TBL] [Abstract][Full Text] [Related]
2. Candida and candidaemia. Susceptibility and epidemiology. Arendrup MC Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246 [TBL] [Abstract][Full Text] [Related]
3. Antifungal susceptibilities of Candida glabrata species complex, Candida krusei, Candida parapsilosis species complex and Candida tropicalis causing invasive candidiasis in China: 3 year national surveillance. Xiao M; Fan X; Chen SC; Wang H; Sun ZY; Liao K; Chen SL; Yan Y; Kang M; Hu ZD; Chu YZ; Hu TS; Ni YX; Zou GL; Kong F; Xu YC J Antimicrob Chemother; 2015 Mar; 70(3):802-10. PubMed ID: 25473027 [TBL] [Abstract][Full Text] [Related]
4. [Antifungal susceptibility profiles of Candida species to triazole: application of new CLSI species-specific clinical breakpoints and epidemiological cutoff values for characterization of antifungal resistance]. Karabıçak N; Alem N Mikrobiyol Bul; 2016 Jan; 50(1):122-32. PubMed ID: 27058336 [TBL] [Abstract][Full Text] [Related]
5. Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance. Pfaller MA; Messer SA; Woosley LN; Jones RN; Castanheira M J Clin Microbiol; 2013 Aug; 51(8):2571-81. PubMed ID: 23720791 [TBL] [Abstract][Full Text] [Related]
6. Isavuconazole, micafungin, and 8 comparator antifungal agents' susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff values. Pfaller MA; Rhomberg PR; Messer SA; Jones RN; Castanheira M Diagn Microbiol Infect Dis; 2015 Aug; 82(4):303-13. PubMed ID: 25986029 [TBL] [Abstract][Full Text] [Related]
7. Candida species distribution and antifungal susceptibility testing according to European Committee on Antimicrobial Susceptibility Testing and new vs. old Clinical and Laboratory Standards Institute clinical breakpoints: a 6-year prospective candidaemia survey from the fungal infection network of Switzerland. Orasch C; Marchetti O; Garbino J; Schrenzel J; Zimmerli S; Mühlethaler K; Pfyffer G; Ruef C; Fehr J; Zbinden R; Calandra T; Bille J; Clin Microbiol Infect; 2014 Jul; 20(7):698-705. PubMed ID: 24188136 [TBL] [Abstract][Full Text] [Related]
9. Multicenter study of epidemiological cutoff values and detection of resistance in Candida spp. to anidulafungin, caspofungin, and micafungin using the Sensititre YeastOne colorimetric method. Espinel-Ingroff A; Alvarez-Fernandez M; Cantón E; Carver PL; Chen SC; Eschenauer G; Getsinger DL; Gonzalez GM; Govender NP; Grancini A; Hanson KE; Kidd SE; Klinker K; Kubin CJ; Kus JV; Lockhart SR; Meletiadis J; Morris AJ; Pelaez T; Quindós G; Rodriguez-Iglesias M; Sánchez-Reus F; Shoham S; Wengenack NL; Borrell Solé N; Echeverria J; Esperalba J; Gómez-G de la Pedrosa E; García García I; Linares MJ; Marco F; Merino P; Pemán J; Pérez Del Molino L; Roselló Mayans E; Rubio Calvo C; Ruiz Pérez de Pipaon M; Yagüe G; Garcia-Effron G; Guinea J; Perlin DS; Sanguinetti M; Shields R; Turnidge J Antimicrob Agents Chemother; 2015 Nov; 59(11):6725-32. PubMed ID: 26282428 [TBL] [Abstract][Full Text] [Related]
10. Antifungal susceptibility testing results of New Zealand yeast isolates, 2001-2015: Impact of recent CLSI breakpoints and epidemiological cut-off values for Candida and other yeast species. Morris AJ; Rogers K; McKinney WP; Roberts SA; Freeman JT J Glob Antimicrob Resist; 2018 Sep; 14():72-77. PubMed ID: 29486358 [TBL] [Abstract][Full Text] [Related]
11. Susceptibility to echinocandins of Candida spp. strains isolated in Italy assessed by European Committee for Antimicrobial Susceptibility Testing and Clinical Laboratory Standards Institute broth microdilution methods. Montagna MT; Lovero G; Coretti C; Martinelli D; De Giglio O; Iatta R; Balbino S; Rosato A; Caggiano G BMC Microbiol; 2015 May; 15():106. PubMed ID: 25990252 [TBL] [Abstract][Full Text] [Related]
12. Real-world experience with echinocandin MICs against Candida species in a multicenter study of hospitals that routinely perform susceptibility testing of bloodstream isolates. Eschenauer GA; Nguyen MH; Shoham S; Vazquez JA; Morris AJ; Pasculle WA; Kubin CJ; Klinker KP; Carver PL; Hanson KE; Chen S; Lam SW; Potoski BA; Clarke LG; Shields RK; Clancy CJ Antimicrob Agents Chemother; 2014; 58(4):1897-906. PubMed ID: 24395235 [TBL] [Abstract][Full Text] [Related]
13. Monitoring Antifungal Resistance in a Global Collection of Invasive Yeasts and Molds: Application of CLSI Epidemiological Cutoff Values and Whole-Genome Sequencing Analysis for Detection of Azole Resistance in Candida albicans. Castanheira M; Deshpande LM; Davis AP; Rhomberg PR; Pfaller MA Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28784671 [TBL] [Abstract][Full Text] [Related]
14. Antifungal susceptibility of Candida species isolated from patients with candidemia in southern Taiwan, 2007-2012: impact of new antifungal breakpoints. Chen YC; Kuo SF; Chen FJ; Lee CH Mycoses; 2017 Feb; 60(2):89-95. PubMed ID: 27621210 [TBL] [Abstract][Full Text] [Related]
15. Comparison of the Sensititre YeastOne colorimetric antifungal panel with CLSI microdilution for antifungal susceptibility testing of the echinocandins against Candida spp., using new clinical breakpoints and epidemiological cutoff values. Pfaller MA; Chaturvedi V; Diekema DJ; Ghannoum MA; Holliday NM; Killian SB; Knapp CC; Messer SA; Miskou A; Ramani R Diagn Microbiol Infect Dis; 2012 Aug; 73(4):365-8. PubMed ID: 22726528 [TBL] [Abstract][Full Text] [Related]
16. Clinical manifestations of candidemia caused by uncommon Candida species and antifungal susceptibility of the isolates in a regional hospital in Taiwan, 2007-2014. Liu WL; Lai CC; Li MC; Wu CJ; Ko WC; Hung YL; Tang HJ; Hsueh PR J Microbiol Immunol Infect; 2019 Aug; 52(4):612-619. PubMed ID: 28886952 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of Two Commercial Broth Microdilution Methods Using Different Interpretive Criteria for the Detection of Molecular Mechanisms of Acquired Azole and Echinocandin Resistance in Four Common Lim HJ; Shin JH; Kim MN; Yong D; Byun SA; Choi MJ; Lee SY; Won EJ; Kee SJ; Kim SH; Shin MG Antimicrob Agents Chemother; 2020 Oct; 64(11):. PubMed ID: 32900684 [TBL] [Abstract][Full Text] [Related]
18. Antifungal susceptibilities of Candida isolates causing bloodstream infections at a medical center in Taiwan, 2009-2010. Huang YT; Liu CY; Liao CH; Chung KP; Sheng WH; Hsueh PR Antimicrob Agents Chemother; 2014 Jul; 58(7):3814-9. PubMed ID: 24752274 [TBL] [Abstract][Full Text] [Related]
19. Prevalence and Antifungal Susceptibility of Pathogenic Yeasts in China: A 10-Year Retrospective Study in a Teaching Hospital. Song Y; Chen X; Yan Y; Wan Z; Liu W; Li R Front Microbiol; 2020; 11():1401. PubMed ID: 32719663 [TBL] [Abstract][Full Text] [Related]
20. Comparison of EUCAST and CLSI broth microdilution methods for the susceptibility testing of 10 systemically active antifungal agents when tested against Candida spp. Pfaller MA; Castanheira M; Messer SA; Rhomberg PR; Jones RN Diagn Microbiol Infect Dis; 2014 Jun; 79(2):198-204. PubMed ID: 24736096 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]